NEW YORK — AXIM®Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM’s proprietary, patent-pending topical ointment formulation AX-1602 that includes the “stem cell cannabinoid” cannabigerol (CBG) and other cannabinoids.
The two indications for AXIM’s AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD) also known as eczema.
Collectively, these conditions will affect nearly two hundred million people worldwide by 2024; combined market estimates are $16 billion by 2022.
Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.
AXIM Biotech presents AX-1602: the world’s first patent-pending formulation containing cannabigerol (CBG) and other cannabinoids as a treatment for psoriasis and atopic eczema.
Dr. Marcus Meinardi leads AXIM Biotech’s AX-1602 human trials with cannabigerol (CBG) and other cannabinoids for psoriasis and eczema at Maurits Clinics in The Hague, The Netherlands.
AXIM’s CEO, Dr. George Anastassov, states, “We are extremely pleased that our ongoing efforts in finding solutions to conditions for which there are no effective treatments or the ones available are associated with significant side effects (e.g. immunosuppression) are culminating with the clinical trials of our Renecann™ product. Psoriasis and atopic dermatitis are debilitating conditions causing significant decrease in quality of life. Utilizing our proprietary technologies and incorporating unique cannabinoids, we believe that we will be able to effectively address these concerns.”
Lekhram Changoer MSc, BSc, AXIM® Chief Technology Officer, states, “We are very excited to begin human dermatological trials for psoriasis and eczema at The Maurits Clinics. Dr. Meinardi is a highly experienced professional and we are glad that his interests are aligned with ours in the utilization of different cannabinoids as the API for finding safe solutions for people with these skin disorders. The AXIM® AX-1602 ointment will be tested with different concentrations of cannabinoids and will be placebo controlled. Following the successful completion of this clinical trial, AXIM® products will be registered as an ointment for various skin disorders.”
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients’ quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other acute (infection) and chronic illnesses.
Although a number of treatment options exist for PsO, there continues to be significant unmet need on the market. The psoriasis market will grow to $10.4 Billion by 2020.
Atopic dermatitis (AD), also known as eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thicken over time. It typically starts in childhood with changing severity over the years. In children under one year of age, much of the body may be affected. As the affected children get older, the back of the knees and front of the elbows are the most common areas affected. In adults, the hands and feet are most commonly affected. Scratching worsens symptoms and affected people have an increased risk of skin infections.
According to the Atopic Dermatitis – Epidemiology Forecast to 2024, there will be 67,630,097 atopic dermatitis cases, and atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022.
AXIM Leads Global Cannabinoid Research and Development:
Cannabigerol (CBG) “the stem cell cannabinoid” has a broad range of biological efficacies. It is a non-psychoactive cannabinoid found in the plant genus Cannabis. Cannabigerol has been found to act as a high affinityα2-adrenergic receptoragonist, moderate affinity 5-HT1A receptorantagonist, and low affinity CB1 receptorantagonist. CBG has also been found to have an anti-nausea and anti-emetic (anti-vomiting) effects.
Further, CBG has demonstrated an anti-inflammatory effect, has also been shown to reduce pain, ease symptoms of psoriasis, act as an antibacterial agent and even slow the proliferation of tumor cells in vitro and in-vivo.
About Dr. Marcus Meinardi:
Dr. Marcus Meinardi has worked since 2005 as a dermatologist at the Maurits Clinics in The Hague, The Netherlands. Dr. Meinardi studied medicine in Rotterdam and then followed his training in Dermatology at the University of Amsterdam. In 1992, he became head of the Department of Dermatology and Allergy. Dr. Meinardi completed his PhD thesis on treatment of psoriasis.
A world leader in cannabis-based drug development, AXIM® Biotech’s core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 888-829-0070.
About AXIM Biotechnologies:
AXIM®Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
These photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227
Source: AXIM Biotechnologies, Inc
Read more: http://www.nasdaq.com/press-release/axim-biotech-begins-human-clinical-trials-with-cannabigerol-cbg-for-psoriasis-and-eczema-in-patients-20160517-00607#ixzz498K6qAKb